Wallace Chan is an Oncology physician. OpenAlex indexes 23 publications with 624 citations (h-index 13); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2200 Northern Blvd
Suite 111
Greenvale, NY 115481219
Telephone
516-325-7500Registry record last updated 3 May 2017.
Clinical trials
- Demoralization Among Palliative Care Patients and Their Family Caregivers in Hong Kong: A Pilot Study
Sponsor: Chinese University of Hong Kong
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
38 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20253 payments
- Novartis Pharmaceuticals CorporationProgram year20254 payments
- Agios Pharmaceuticals, Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
53.6%Kinase inhibitor33.5%Tagrisso32%Imatinib Mesylate20%Mekinist17%Bosulif16%Tafinlar15%Part D<11 patientsAntimetabolite20.1%Hydroxyurea100%Part D≥12 patientsMetabolism & gastrointestinal
25.9%Corticosteroid13.8%Prednisone100%Part D≥17 patientsSerotonin-3 Receptor Antagonist6.7%Ondansetron Odt100%Part D<11 patients+ 1 more class in this area
Nervous system
12.1%Opioid Agonist12.1%Oxycodone Hcl59%Hydromorphone Hcl41%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma
Nature Communications
2022 - In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs
Scientific Reports
2022 - Computational Identification of Possible Allosteric Sites and Modulators of the SARS-CoV-2 Main Protease
Journal of Chemical Information and Modeling
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”